RHUMBLINE ADVISERS - TG THERAPEUTICS INC ownership

TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 101 filers reported holding TG THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of TG THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,581,749
-66.4%
189,206
-0.1%
0.00%
-60.0%
Q2 2023$4,706,186
+174332.4%
189,460
+5.6%
0.01%
+66.7%
Q1 2023$2,698
+33.1%
179,420
+4.7%
0.00%0.0%
Q4 2022$2,027
-99.8%
171,303
+5.4%
0.00%
+200.0%
Q3 2022$962,000
+49.4%
162,531
+7.3%
0.00%0.0%
Q2 2022$644,000
-48.7%
151,487
+14.7%
0.00%
-50.0%
Q1 2022$1,256,000
-49.7%
132,038
+0.4%
0.00%
-33.3%
Q4 2021$2,498,000
-43.5%
131,485
-1.1%
0.00%
-50.0%
Q3 2021$4,424,000
-12.8%
132,945
+1.7%
0.01%
-14.3%
Q2 2021$5,071,000
-27.0%
130,723
-9.3%
0.01%
-22.2%
Q1 2021$6,944,000
-9.6%
144,062
-2.5%
0.01%
-18.2%
Q4 2020$7,685,000
+119.0%
147,741
+12.7%
0.01%
+120.0%
Q3 2020$3,509,000
+21.4%
131,120
-11.6%
0.01%0.0%
Q2 2020$2,890,000
+148.1%
148,350
+25.3%
0.01%
+150.0%
Q1 2020$1,165,000
+3.3%
118,443
+16.6%
0.00%0.0%
Q4 2019$1,128,000
+110.1%
101,624
+6.2%
0.00%
+100.0%
Q3 2019$537,000
-33.8%
95,679
+2.1%
0.00%
-50.0%
Q2 2019$811,000
+29.8%
93,703
+20.6%
0.00%
+100.0%
Q1 2019$625,000
+93.5%
77,713
-1.5%
0.00%0.0%
Q4 2018$323,000
+11.0%
78,898
+51.7%
0.00%0.0%
Q3 2018$291,000
-59.5%
52,018
-4.7%
0.00%0.0%
Q2 2018$718,000
+9.6%
54,587
+18.3%
0.00%0.0%
Q1 2018$655,000
+79.0%
46,152
+3.3%
0.00%0.0%
Q4 2017$366,000
-42.1%
44,672
-16.2%
0.00%0.0%
Q3 2017$632,000
+19.5%
53,292
+1.3%
0.00%0.0%
Q2 2017$529,000
+8.2%
52,602
+25.2%
0.00%0.0%
Q1 2017$489,000
+158.7%
42,017
+3.6%
0.00%
Q4 2016$189,000
-35.3%
40,549
+7.5%
0.00%
-100.0%
Q3 2016$292,000
+28.1%
37,737
+0.5%
0.00%0.0%
Q2 2016$228,000
-22.2%
37,547
+9.0%
0.00%0.0%
Q1 2016$293,000
-28.5%
34,440
+0.1%
0.00%0.0%
Q4 2015$410,000
+26.9%
34,400
+7.5%
0.00%0.0%
Q3 2015$323,000
-40.1%
32,005
-1.5%
0.00%
-50.0%
Q2 2015$539,000
+30.5%
32,494
+21.9%
0.00%
+100.0%
Q1 2015$413,000
+27.5%
26,654
+30.3%
0.00%0.0%
Q4 2014$324,000
+60.4%
20,459
+8.2%
0.00%0.0%
Q3 2014$202,000
+14.8%
18,914
+1.1%
0.00%0.0%
Q2 2014$176,000
+141.1%
18,714
+76.1%
0.00%
Q1 2014$73,000
+65.9%
10,626
-5.5%
0.00%
Q4 2013$44,000
-25.4%
11,246
-2.6%
0.00%
Q3 2013$59,000
-16.9%
11,546
+3.4%
0.00%
Q2 2013$71,00011,1700.00%
Other shareholders
TG THERAPEUTICS INC shareholders Q1 2017
NameSharesValueWeighting ↓
RA Capital Management 6,880,323$38,633,0002.30%
Eversept Partners, LP 773,501$4,343,2081.35%
Opaleye Management Inc. 612,500$3,439,0001.24%
BRIDGER MANAGEMENT, LLC 2,334,196$13,107,0001.08%
Sofinnova Investments, Inc. 1,733,628$9,734,0000.88%
PURA VIDA INVESTMENTS, LLC 354,719$1,992,0000.34%
683 Capital Management, LLC 400,000$2,246,0000.25%
NEXPOINT ASSET MANAGEMENT, L.P. 649,460$3,646,0000.23%
Artal Group S.A. 900,000$5,054,0000.20%
Frontier Wealth Management LLC 226,750$1,273,0000.19%
View complete list of TG THERAPEUTICS INC shareholders